Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jul 22;11(2):227-232.
doi: 10.1159/000517692. eCollection 2021 May-Aug.

Nintedanib-Induced Renal Thrombotic Microangiopathy

Affiliations
Case Reports

Nintedanib-Induced Renal Thrombotic Microangiopathy

Takeshi Fujita et al. Case Rep Nephrol Dial. .

Abstract

Nintedanib is a unique tyrosine kinase inhibitor used to suppress fibrosis in patients with idiopathic pulmonary fibrosis (IPF). Nintedanib has been shown to suppress multiple processes of fibrosis, thereby reducing the rate of lung function decline in patients with IPF. Since vascular endothelial growth factor is one of this agent's targets, nephrotoxicity, including renal thrombotic microangiopathy (TMA), is a possible major adverse effect. However, only 2 previous cases of nintedanib-induced renal TMA have been published. Our patient was an 83-year-old man with IPF. As adverse effects including liver enzyme level elevation, diarrhoea, anorexia, and nephrotoxicity developed, the nintedanib dosage was reduced after 9 months. The digestive symptoms resolved promptly, but the proteinuria and reduced kidney function remained. Although the kidney injury had improved to some extent, we performed a percutaneous renal biopsy. The biopsy revealed typical TMA findings such as microaneurysms filled with pale material, segmental double contours of glomerular basement membranes, and intracapillary foam cells. After discontinuation of nintedanib, the patient's nephrotoxicity improved. Nintedanib-induced renal TMA is reversible and is possibly dose-dependent. Here, we report the clinical course of our case and review the characteristics of nintedanib-induced renal TMA.

Keywords: Drug-induced kidney injury; Idiopathic pulmonary fibrosis; Nephrotic syndrome; Nintedanib; Proteinuria; Thrombotic microangiopathy; Tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Clinical course of the present case regarding urine protein, serum Cr, and serum albumin levels. Cr, creatinine.
Fig. 2
Fig. 2
The pathological features of nintedanib-induced glomerular thrombotic angiopathy. a Light microscopy with periodic acid-Schiff staining shows typical microaneurysms filled with pale material (black arrows), segmental double contours of glomerular basement membranes (white arrow), and intracapillary foam cells (asterisks) (original magnification ×400). b Electron microscopy shows microaneurysmal dilatation of a capillary loop with marked widening of the subendothelial spaces (arrows) (original magnification ×1,500).

References

    1. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007 Feb;49((2)):186–93. - PubMed
    1. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. VEGF Inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358((11)):1129–36. - PMC - PubMed
    1. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens. 2010 May;23((5)):460–8. - PubMed
    1. Cheungpasitporn W, Chebib FT, Cornell LD, Brodin ML, Nasr SH, Schinstock CA, et al. Intravitreal antivascular endothelial growth factor therapy may induce proteinuria and antibody mediated injury in renal allografts. Transplantation. 2015 Nov;99((11)):2382–6. - PubMed
    1. Piscitani L, Sirolli V, Di Liberato L, Morroni M, Bonomini M. Nephrotoxicity associated with novel anticancer agents (aflibercept, dasatinib, nivolumab): case series and nephrological considerations. Int J Mol Sci. 2020 Jul 10;21((14)):4878. - PMC - PubMed

Publication types